HCATHealthcare · Health Information ServicesThe 6 Wall Street analysts covering Health Catalyst, Inc. hold a median 12-month price target of $1.9 — +11.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 2 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Health Catalyst, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (15): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HCAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.1% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | Canaccord Genuity | Downgrade | Hold | $3.00 → $1.80 |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $1.75 → $1.50 |
| 11 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 11 Aug 2026 | Citigroup | Maintains | Neutral | $2.50 → $2.00 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $2.00 → $3.00 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 June 2026 | Wells Fargo | Maintains | Equal-Weight | $1.00 → $1.75 |
| 26 June 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 May 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 18 Mar 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 13 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 13 Mar 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 13 Mar 2026 | Stifel | Maintains | Hold | — |
| 9 Jan 2026 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | Stifel | Maintains | Hold | — |
| 11 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCAT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Health Catalyst, Inc. returned −47.2% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 84% of US stocks
Cheaper than 65% of US stocks
Cheaper than 21% of US stocks
Higher than 14% of US stocks
Higher than 62% of US stocks
Higher than 27% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Health Catalyst, Inc. has a market value of $128.7M and an enterprise value of $190.0M.
Revenue in the twelve months to 30 June 2026: $292.2M. The latest quarter shrank 12.7% year on year.
Net income over the same four quarters: −$264.8M, a −90.6% net margin.
Diluted earnings per share, trailing twelve months: $−3.68.
Free cash flow in the twelve months to 30 June 2026: $6.6M, after $19.1M of capital spending.
Health Catalyst, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −0.7×; forward P/E: 217.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Health Catalyst, Inc. employs 1,200 people — $244K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Health Catalyst, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Health Catalyst announced that senior management members will participate in the 2026 Wells Fargo Healthcare Conference in Boston on September 9-10, 2026.
Why it matters — The participation offers HCAT watchers a public venue for management to present the company's outlook and engage with investors at a major industry conference.
Health Catalyst reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook. The company also outlined a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.
Why it matters — The earnings results and post-divestiture strategic shift indicate how HCAT is positioned after reshaping its business portfolio.
Health Catalyst, Inc. published the transcript of its Q2 2026 earnings call, as reported by Seeking Alpha. The excerpt contains only the transcript headline with no financial figures or management commentary.
Why it matters — HCAT watchers would review the earnings call transcript for management's discussion of the company's quarterly performance and outlook.
Zacks Investment Research reports that Health Catalyst's revenue and EPS for the quarter ended June 2026 provide a view of business performance relative to Wall Street estimates and year-ago figures. The report examines how key metrics compare with those benchmarks.
Why it matters — HCAT watchers would care because the comparison of key metrics to Wall Street estimates and prior-year results offers insight into the company's quarterly operating performance.
Health Catalyst reported Q2 earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share, and also surpassed revenue estimates. The result matches the $0.04 per share the company posted a year ago.
Why it matters — HCAT watchers would note that the company exceeded analyst expectations for both earnings and revenue in the quarter.
The 6 Wall Street analysts covering Health Catalyst, Inc. have a median 12-month price target of $1.9, with estimates ranging from $1.5 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Health Catalyst, Inc., 1 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Health Catalyst, Inc. 48 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Health Catalyst, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +11.1% from the last close, and Ticker Nerd's factor model ranks Health Catalyst, Inc. 48 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Health Catalyst, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $2 over the next 12 months.
Health Catalyst, Inc. returned -47.2% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Health Catalyst, Inc. is a healthcare data and analytics technology company that provides software and services to healthcare organizations.
The most recent item we track (GlobeNewsWire, 31 Aug 2026): "Health Catalyst to Participate in Upcoming Investor Conference". Health Catalyst announced that senior management members will participate in the 2026 Wells Fargo Healthcare Conference in Boston on September 9-10, 2026.
Health Catalyst, Inc. is a healthcare data and analytics technology company that provides software and services to healthcare organizations. Health Catalyst, Inc. focuses on helping hospitals, health systems, and other providers unify clinical, financial, and operational data through its analytics platform and related applications. Its offerings support areas such as quality improvement, population health, revenue cycle performance, and cost management, enabling organizations to turn fragmented information into actionable insights. The company also delivers professional services that help clients implement, configure, and use its technology more effectively. Health Catalyst, Inc. plays a role in the health information services market by supplying tools that support data-driven decision-making across the healthcare industry.
CEO Mr. Benjamin Albert · 1,200 employees · United States · https://www.healthcatalyst.com
